Document Detail

Probenecid as a Noninjurious Positive Inotrope in an Ischemic Heart Disease Murine Model.
MedLine Citation:
PMID:  23241275     Owner:  NLM     Status:  Publisher    
The current therapeutic options for acute decompensated heart failure are limited to afterload reducers and positive inotropes. The latter increases myocardial contractility through changes in myocyte calcium (Ca(2+)) handling (mostly through stimulation of the β-adrenergic pathways [β-ADR]) and is associated with paradoxical effects of arrhythmias, cell death, and subsequently increased mortality. We have previously demonstrated that probenecid can increase cytosolic Ca(2+) levels in the cardiomyocyte resulting in an improved inotropic response in vitro and in vivo without activating the β-ADR system. We hypothesize that, in contrast to other commonly used inotropes, probenecid functions through a system separate from that of β-ADR and hence will increase contractility and improve function without damaging the heart. Furthermore, our goal was to evaluate the effect of probenecid on cell death in vitro and its use in vivo as a positive inotrope in a mouse model of ischemic cardiomyopathy. Herein, we demonstrate that probenecid induced an influx of Ca(2+) similar to isoproterenol, but does not induce cell death in vitro. Through a series of in vivo experiments we also demonstrate that probenecid can be used at various time points and with various methods of administration in vivo in mice with myocardial ischemia, resulting in improved contractility and no significant difference in infarct size. In conclusion, we provide novel data that probenecid, through its activity on cellular Ca(2+) levels, induces an inotropic effect without causing or exacerbating injury. This discovery may be translatable if this mechanism is preserved in man.
Sheryl E Koch; Michael Tranter; Nathan Robbins; Kristin Luther; Umesh Singh; Min Jiang; Xiaoping Ren; Trisha Tee; Leah Smith; Priyanka Varma; W Keith Jones; Jack Rubinstein
Related Documents :
20547705 - Coronary artery bypass graft and mitral valvuloplasty in a patient with isolated ventri...
3905055 - Indications for coronary artery bypass surgery in patients with chronic angina pectoris...
9769005 - Off-pump multivessel coronary bypass via sternotomy is safe and effective.
7893495 - Myocardial revascularization with bilateral internal thoracic artery in patients with l...
1807495 - Ventricular assistance by right free wall dynamic cardiomyoplasty following acute right...
11410555 - Left ventricular dysfunction, natriuretic peptides, and mortality in an urban population.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-12-14
Journal Detail:
Title:  Journal of cardiovascular pharmacology and therapeutics     Volume:  -     ISSN:  1940-4034     ISO Abbreviation:  J. Cardiovasc. Pharmacol. Ther.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-12-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602617     Medline TA:  J Cardiovasc Pharmacol Ther     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
1Division of Cardiovascular Diseases, Department of Internal Medicine, University of Cincinnati, Cincinnati, OH, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Prediction of adult height by Tanner-Whitehouse method in young Caucasian male athletes.
Next Document:  Current status of health technology reassessment of non-drug technologies: survey and key informant ...